SpendQueryBeta

Contracting office · 75A501

Barda - Aspr / Daappo / Barda Dcma

Office of Assistant Secretary for Preparedness and Response · Department of Health and Human Services

At a glance

  • 238 active contracts, $18.02B
  • 56% of its 536 competed contracts drew a single offer (last 3 years)
  • Usually buys through: Standalone contract

Money by year

  • FY2023$5.78B
  • FY2024$4.02B
  • FY2025$525.96M
  • FY2026$2.32B

Obligations (money committed) in prime awards, from USAspending.gov.

What it buys, FY2025

  1. 541714 Research and Development in Biotechnology (Except Nanobiotechnology) $792.54M
  2. 325412 Pharmaceutical Preparation Manufacturing $150.26M
  3. 541611 Administrative Management and General Management Consulting Services $31.68M
  4. 236210 Industrial Building Construction $31.52M
  5. 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) $19.42M
  6. 541990 All Other Professional, Scientific, and Technical Services $3.64M
  7. 334519 Other Measuring and Controlling Device Manufacturing $3.30M
  8. 112990 All Other Animal Production $3.14M

Who it buys from, FY2025

  1. Bavarian Nordic A/S $143.57M
  2. Start2 Group, Inc. $105.22M
  3. Sanofi $99.13M
  4. Emergent Biosolutions Inc. $95.67M
  5. Amgen USA Inc $89.93M
  6. Seqirus Inc $86.16M
  7. Albert B. Sabin Vaccine Institute, Inc. (The) $70.39M
  8. Basilea Pharmaceutica Ag $63.70M
  9. Cidara Therapeutics Inc $58.05M
  10. Siga Technologies Inc $53.12M

Contracts ending in the next 12 months

67 contracts, $6.16B with options. The largest:

ContractIncumbentEndsValue with options
75A50122C00010
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF A SECOND-GENERATION, MULTI-ANALYTE MOLECULAR SARS-COV-2 AND INFLUENZA A/B TEST THAT HAS A REDUCED TIME TO RESULT AND INCREASED SENSITIVITY THAT CAN BE USED AT HOME OR A POC SETTING
Detect Inc2026-10-26$34.71M
75A50122F80001
TRAVEL SUPPORT SERVICES
Wits Solutions Inc.2026-10-30$5.37M
75A50120C00180
VAXXAS - DEVELOPMENT OF HD-MICRO ARRAY PATCH (MAP) TO DELIVER A VACCINE AGAINST A PANDEMIC STRAIN OF INFLUENZA, H5N1.
Vaxxas Pty LTD2026-12-30$29.59M
75A50124C00062
DEVELOPMENT OF HOPO-101 AS AN MCM (MEDICAL COUNTERMEASURE) DECORPORATION AGENT FOR THE TREATMENT OF INDIVIDUALS WITH KNOWN OR SUSPECTED INTERNAL CONTAMINATION WITH RADIONUCLIDES (THE ?MCM INDICATION?) AND/OR TOXIC HEAVY METALS OF INTEREST FOR COMMERC
Hopo Therapeutics, Inc.2026-12-31$231.15M
75A50122C00082
THIS ACQUISITION WILL ALLOW BARDA TO INVEST PROJECT BIOSHIELD FUNDS FOR LATE-STAGE CLINICAL DEVELOPMENT, REGULATORY APPROVAL FOR 2-PAM AUTOINJECTORS (AS A DRUG/DEVICE COMBINATION PRODUCT) TO TREAT ORGANOPHOSPHATE (OP) POISONING, INCLUDING NERVE AGENT
Aktivax, Inc.2026-12-31$220.25M
75A50120C00169
CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS
Locus Biosciences Inc2026-12-31$109.82M
75A50120C00097
THIS SYSTEM WOULD BE USED AND INTEGRATED WITHIN ROUTINE CARE FOR BURNS AND TRAUMATIC INJURIES, BUT WOULD ALSO HAVE THE POTENTIAL TO BE OF USE IN DETECTION VIRAL PNEUMONIA OF COVID 19 CASES.
Philips North America LLC2026-12-31$68.17M
HHSO100201600017C
IGF::OT::IGF - DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES)
Dnae Group Holdings Limited2026-12-31$61.91M
75A50122C00072
ENALARE THERAPEUTICS: AN AGNOSTIC RESPIRATORY STIMULANT FOR USE AS A MEDICAL COUNTERMEASURE TO TREAT RESPIRATORY DEPRESSION
Enalare Therapeutics Inc2026-12-31$56.58M
75A50122C00017
THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES PRECLINICAL, REGULATORY, AND MANUFACTURING DEVELOPMENT ACTIVITIES.
Keranetics Inc.2026-12-31$5.91M

All of them, with filters →

Open notices

All 1 open notices →

From USAspending.gov prime awards and SAM.gov notices. Sources and limits